ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

Showing results for Cancer Research

October 13, 2020

The Association for Clinical Oncology (ASCO) joined more than 110 organizations representing patients, medical researchers, providers, cancer survivors and their families in signing an endorsement letter for S. 4742, the CLINICAL TREATMENT Act.

October 1, 2020

The Continuing Resolution provides flat funding for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA) through December 11, 2020, and does not include any emergency or additional funding for the NIH to mitigate disruptions to trials/research due to COVID-19.

October 1, 2020

Two-thirds of Americans report that their scheduled cancer screenings, such as mammograms and colonoscopies, have been delayed or skipped in the midst of the COVID-19 crisis, according to the American Society of Clinical Oncology’s fourth annual National Cancer Opinion Survey.

September 30, 2020

ASCO applauds Senators Richard Burr (R-NC) and Ben Cardin (D-MD) for introducing bipartisan legislation to expand access to clinical trials and improve the quality of cancer research. The CLINICAL TREATMENT Act (S. 4742) would require Medicaid to guarantee coverage of the routine care costs of clinical trial participation for Medicaid enrollees with a life-threatening condition.

September 24, 2020

On September 24, a multinational consortium of organizations in the cancer field is hosting the annual World Cancer Research Day, which aims to raise awareness about the importance of further developing and boosting cancer research as a crucial part of slowing the diseases’ progression and improving survival rates and quality of life for those affected.

September 2, 2020

While cancer remains the second leading cause of death in high-income countries, cancer-related mortality has been steadily declining thanks to a wide range of advances. Today, ASCO’s Chief Medical Officer and Executive Vice President Richard L. Schilsky, MD, FACP, FSCT, FASCO, and co-authors Sharyl Nass, PhD, Michelle M. Le Beau, PhD, and Edward J. Benz, Jr., MD, highlight the major advances in cancer care over the last 50 years as part of a special series of articles in the New England Journal of Medicine commemorating the 50 year anniversary of the National Academy of Medicine.

September 1, 2020

On Monday, August 23, ASCO President Lori J. Pierce, MD, FASTRO, FASCO, and Stand Up To Cancer (SU2C) Health Equity Committee Chair Edith Perez, MD, met virtually to discuss the importance of health equity and the work ASCO and Stand Up To Cancer are doing to increase diversity in cancer research and treatment.

August 31, 2020

On September 16, the Association for Clinical Oncology (ASCO) will be hosting its first ever completely virtual Advocacy Summit. Oncology care providers from across the United States will meet with Members of Congress and their staff by phone or video to advocate for policies that will improve access to high-quality, equitable care for people with cancer and ensure robust funding for cancer research.

August 14, 2020

The American Society of Clinical Oncology (ASCO) invites you to help shape a new initiative to foster participation in cancer treatment trials to more fully reflect the diversity of people at risk for or living with cancer. As part of the ASCO and the Association of the Community Cancer Centers (ACCC) recently announced collaboration, ASCO is seeking novel strategies and practical solutions to increase participation of under-represented racial and ethnic populations in cancer treatment trials. The ASCO-ACCC Request for Ideas closes August 24, and submissions are being accepted online. 

July 27, 2020

On July 24, 2020, the U.S. Food and Drug Administration approved Tecartus (brexucabtagene autoleucel), a cell-based gene therapy for treatment of adult patients diagnosed with mantle cell lymphoma (MCL) who have not responded to or who have relapsed following other kinds of treatment. Tecartus, a chimeric antigen receptor (CAR) T cell therapy, is the first cell-based gene therapy approved by the FDA for the treatment of MCL.

July 21, 2020

The American Society of Clinical Oncology (ASCO) and Association of Community Cancer Centers (ACCC) today announced a new collaboration to foster participation in cancer treatment trials to more fully reflect the diversity of people at risk for or living with cancer.

July 21, 2020

The US Food and Drug Administration (FDA) recently finalized four new final Guidance for Industry documents for cancer clinical trial eligibility criteria that describe ways that clinical trials can safely include patients who have historically been excluded. The guidance documents complement ongoing work by ASCO and Friends of Cancer Research (Friends) to eliminate overly restrictive eligibility criteria that can exclude patients from trials without scientific or participant safety justification. Clinical trials provide patients with cancer access to promising investigational therapies – which are sometimes the only treatment option available – and advance clinical care by producing safety and efficacy data about new therapies.

July 10, 2020

The American Society of Clinical Oncology (ASCO) and the U.S. Food and Drug Administration (FDA) will be holding the 2020 Clinical Outcome Assessments in Cancer Clinical Trials Fifth Annual Workshop, which will be fully virtual. The goal of the workshop is to provide a detailed discussion for creating regulatory-grade patient-reported data on tolerability. 

June 9, 2020

The Association of Community Cancer Centers (ACCC) and the American Society of Clinical Oncology (ASCO) held a special live webcast on the ASCO Survey on COVID-19 in Oncology Registry (ASCO Registry). A recording is now available.

May 12, 2020

The Association for Clinical Oncology (ASCO) recently sent a letter to House and Senate leadership urging their support for policies to increase diversity in clinical trials, including the CLINICAL TREATMENT Act (H.R. 913), in a future COVID-19 response package.

Pages